Genmab A/S
NASDAQ:GMAB
Intrinsic Value
Genmab A/S operates as an international biotechnology company. [ Read More ]
The intrinsic value of one GMAB stock under the Base Case scenario is 31.21 USD. Compared to the current market price of 35.27 USD, Genmab A/S is Overvalued by 12%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up to access Genmab A/S's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Genmab A/S
| Current Assets | 29.7B |
| Cash & Short-Term Investments | 24.9B |
| Receivables | 4.8B |
| Other Current Assets | 51m |
| Non-Current Assets | 2.2B |
| Long-Term Investments | 183m |
| PP&E | 1.6B |
| Intangibles | 129m |
| Other Non-Current Assets | 283m |
| Current Liabilities | 2B |
| Other Current Liabilities | 2B |
| Non-Current Liabilities | 1.2B |
| Long-Term Debt | 721m |
| Other Non-Current Liabilities | 509m |
GMAB Profitability Score
Profitability Due Diligence
Genmab A/S's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
Score
Genmab A/S's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
GMAB Solvency Score
Solvency Due Diligence
Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GMAB Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for GMAB is 110.14 USD with a low forecast of 27.84 USD and a high forecast of 417.65 USD.
Shareholder Return
GMAB Price
Genmab A/S
| Average Annual Return | 29.22% |
| Standard Deviation of Annual Returns | 32.55% |
| Max Drawdown | -25% |
| Market Capitalization | 164B DKK |
| Shares Outstanding | 66 057 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Contact
IPO
Employees
Officers
The intrinsic value of one GMAB stock under the Base Case scenario is 31.21 USD.
Compared to the current market price of 35.27 USD, Genmab A/S is Overvalued by 12%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
